Story
Samsung Biologics Makes $1.8 Billion All-Cash Bid for PolyPeptide
Summary
The South Korean contract drug manufacturer aims to acquire Swiss-based PolyPeptide to expand its capabilities in high-growth peptide therapeutics, including obesity and diabetes treatments.
South Korea’s Samsung Biologics has announced it will launch a 1.46 billion Swiss francs ($1.81 billion) all-cash tender offer for Swiss contract drugmaker PolyPeptide. The move signals a strategic push into the rapidly expanding market for peptide-based drugs.
Offer Details
The proposed offer is for 44.31 Swiss francs per share, which represents a premium of approximately 6.1% over PolyPeptide's last closing price of 41.75 Swiss francs, according to a Reuters calculation. Both companies confirmed the bid in separate statements.
The public tender offer is expected to begin by the end of August and is anticipated to close by the end of the year, Samsung Biologics said. Following the acquisition, the company plans to pursue a squeeze-out of any remaining minority shareholders and delist PolyPeptide from the SIX Swiss Exchange, making it a wholly owned subsidiary.
Strategic Rationale
This acquisition is set to significantly enhance Samsung Biologics' manufacturing capabilities in peptide-based therapeutics. The company specifically highlighted the fast-growing class of obesity and diabetes treatments, such as GLP-1 drugs, as a key area of focus.
AdBy integrating PolyPeptide's expertise, Samsung Biologics positions itself to capitalize on the high demand for contract manufacturing services in one of the pharmaceutical industry's most dynamic sectors.
Board and Shareholder Support
The deal has received strong backing from key stakeholders. PolyPeptide's board of directors has unanimously recommended that its shareholders accept the offer.
Crucially, PolyPeptide’s largest shareholder, Draupnir Holding, has already agreed to tender all of its shares. Draupnir holds approximately 55.65% of the company, providing a clear path for the acquisition's approval.
Read next
More on Stocks
MOEX Russia Index Closes Flat Amid Mixed Trading and Falling Oil Prices
Russia's benchmark stock index, the MOEX, finished the trading session unchanged as gains in consumer and materials stocks were offset by weakness in other sectors. The flat close came despite a drop in global oil prices and a strengthening of the Russian ruble.
Boeing 737 MAX Software Glitch Affects Autopilot, Prompts FAA Review
Boeing has identified a software flaw in its 737 MAX jets that can disable some automated navigation functions during certain landing scenarios, according to a Wall Street Journal report. The issue has prompted an FAA investigation and requests from major U.S. airlines to halt deliveries of aircraft with the new software.
Trump Announces New Fuel Economy Rules to End Biden-Era EV Push
Former President Donald Trump stated he has approved new fuel economy standards designed to reverse the Biden administration's policies that encouraged electric vehicle production. The move, announced on social media, signals a major shift in U.S. automotive regulatory policy.
Boeing Discloses 737 MAX Software Flaw Affecting Landing Navigation
Boeing has identified a software glitch in its 737 MAX aircraft that could disable an automated navigation feature during landing, prompting an investigation by the FAA and requests from major airlines to avoid the flawed update.